Caribou Biosciences (CRBU) Depreciation and Depletion (2020 - 2022)
Caribou Biosciences (CRBU) posted quarterly Depreciation and Depletion of $400000.0 for Q2 2022, up 100.0% year-over-year from $200000.0 in Q2 2021, and up 33.33% quarter-over-quarter from $300000.0 in Q1 2022.
Caribou Biosciences (CRBU) Depreciation and Depletion (2020 - 2022) Analysis & Trends
Caribou Biosciences (CRBU) has reported Depreciation and Depletion for 3 consecutive years, with $400000.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Depreciation and Depletion rose 100.0% year-over-year to $400000.0; the TTM figure through Jun 2022 stood at $301000.0 (down 66.56% YoY), while the FY2021 annual figure was $1000.0, down 99.89% from the prior year.
- Depreciation and Depletion climbed to $400000.0 in Q2 2022 per CRBU's latest filing, from $300000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $400000.0 in Q2 2022 and bottomed at -$699000.0 in Q4 2021.
- Historically, Depreciation and Depletion has averaged $155666.7 across 3 years, with a median of $200000.0 in 2020.
- Annual changes were most pronounced in 2021 — Depreciation and Depletion slumped 449.5% — and 2022, when it jumped 100.0%.
- Caribou Biosciences' Depreciation and Depletion stood at $200000.0 in 2020, then plunged by 449.5% to -$699000.0 in 2021, then jumped by 157.22% to $400000.0 in 2022.
- Business Quant data shows CRBU's Depreciation and Depletion at $400000.0 in Q2 2022, $300000.0 in Q1 2022, and -$699000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | -699,000.00 |
| Dec 31, 2021 | -699,000.00 |
| Sep 30, 2021 | 300,000.00 |
| Sep 30, 2021 | 300,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Mar 31, 2021 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Dec 31, 2020 | 200,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 200,000.00 |
| Jun 30, 2020 | 200,000.00 |